Duloxetine and Neurofeedback Training for the Treatment of Chemotherapy Induced Peripheral Neuropathy
-
- STATUS
- Recruiting
-
- End date
- Oct 31, 2022
-
- participants needed
- 380
-
- sponsor
- M.D. Anderson Cancer Center
Summary
This phase II trial investigates how well duloxetine and neurofeedback training work in treating patients with chemotherapy induced peripheral neuropathy. Duloxetine is a type of serotonin and norepinephrine reuptake inhibitor that increases the amount of certain chemicals in the brain that help relieve depression and peripheral neuropathy. Neurofeedback training is a type of therapy that uses an electroencephalograph (EEG) and a computer software program to measure brain wave activity and may help teach patients with peripheral neuropathy (nerve damage) how to change their own brain waves to lower their feelings of neuropathy and help improve their overall quality of life. Giving duloxetine and neurofeedback training may work better in treating peripheral neuropathy caused by chemotherapy compared to duloxetine or neurofeedback training alone.
Description
PRIMARY OBJECTIVE:
I. Determine if the combination of duloxetine (DL) and neurofeedback (NFB) is superior to DL or NFB alone in treating chemotherapy induced peripheral neuropathy (CIPN).
SECONDARY OBJECTIVES:
I. Determine the optimal number of neurofeedback sessions needed to result in long-term relief of CIPN in a large cohort of cancer survivors and across socioeconomic groups.
II. Examine baseline brain signatures as a predictor of response to neurofeedback (NFB) and to duloxetine and determine who will require more sessions of NFB to achieve relief of symptoms.
III. Examine if the combination of DL + NFB (than those getting DL or NFB alone) or a larger number of NFB sessions results in better improvements in cancer-related symptoms, physical functioning, and quality of life (QOL).
OUTLINE: Patients are randomized to 1 of 3 groups.
GROUP I: Patients receive neurofeedback training over 1 hour each 3-5 times weekly for up to 5 weeks. Patients also receive duloxetine orally (PO) once daily (QD) for 5 weeks in the absence of unacceptable toxicity.
GROUP II: Patients receive neurofeedback training session over 1 hour 3-5 times weekly for up to 5 weeks.
GROUP III: Patients receive duloxetine PO QD for 5 weeks in the absence of unacceptable toxicity.
After completion of study, patients are followed up at 6 and 12 months.
Details
| Condition | Hematologic Malignancy, Blood Cancer, Hematologic Cancer, Hematologic Neoplasms, Malignant Solid Tumor, Chemotherapy Induced Peripheral Neuropathy, Malignant Solid Neoplasm, Blood Cancer, Hematologic Cancer, Hematologic Neoplasms, hematopoietic and lymphoid cell neoplasm, hematopoietic malignancy |
|---|---|
| Treatment | questionnaire administration, quality-of-life assessment, Duloxetine, Neurofeedback |
| Clinical Study Identifier | NCT04560673 |
| Sponsor | M.D. Anderson Cancer Center |
| Last Modified on | 25 January 2021 |
How to participate?
,
You have contacted , on
Your message has been sent to the study team at ,
What happens next?
- You can expect the study team to contact you via email or phone in the next few days.
- Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.
You are contacting
Primary Contact
Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.
Learn moreIf you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.
Learn moreComplete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.
Learn moreSimilar trials to consider
Browse trials for
Not finding what you're looking for?
Sign up as a volunteer to stay informed
Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.
Sign up as volunteer